Research and Markets: The U.S. Market for DNA-Based Infectious Disease Tests Is Today a $1.1 Billion Industry - Read More Details Inside Market Analysis & Directions Report

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/8325d9/us_dnabased_diagn) has
announced the addition of the "US DNA-Based Diagnostic Test and Equipment Market
Analysis & Directions" report to their offering.

DNA-based diagnostics are established in laboratory medicine with many of the
top tests run for infectious disease. The U.S. market for DNA-based infectious
disease tests is today a $1.1 billion industry. Nucleic acid testing (NAT) is
used to screen blood supplies; DNA-based tests are rapidly emerging as an
oncology standard as well; and newer tests are more slowly developing as a way
to treat other non-infectious diseases such as chronic diseases and diseases of
aging. However, they still operate largely outside of core medical practice
today - which is the doctor's office and hospital lab. Evidence that DNA-based
testing can appreciably improve the quality of healthcare is still murky, but
policymakers and scientific researchers believe that DNA-based diagnostics (also
called genomics-based molecular diagnostics) will change the way medicine is
practiced in the coming decades.

This USA report examines the key players and issues in commercializing DNA-based
diagnostics in the United States. It covers the market for testing products for
infectious diseases, human cancers and pharmacogenomics, and the instrumentation
needed to perform the tests. It analyzes U.S. market structure and size by major
product segments. It covers distribution structure; development trends and
technology advances; regulations and policies for genetic privacy, insurance
coverage and DNA counseling; and a future market outlook through 2012 -
including market drivers and obstacles.

The report contains profiles of 15 companies including U.S.-based public and
private companies: Abbott Molecular Diagnostics, Celera, Genomic Health, Myriad
Genetics, Gen-Probe and Life Technologies (formerly Applied Biosystems). For key
players such as Siemens Healthcare, BioMérieux and Qiagen, whose core business
operates in non-U.S. regions, we cover their U.S.-oriented activities and
product portfolios. Others covered: Novartis V&D, Becton Dickinson, Interleukin
Genetics, Hologic/Third Wave Technologies, and Decode. Most of the
market-leading companies cater to the traditional medical channel and regulatory
path, although companies having great success with largely unregulated
laboratory-developed tests also factor into this report. Newer companies selling
personal genomic scans directly to consumers are growing in number but are not
the primary focus here, although they are covered briefly in the section C ( 27
companies).

Key Topics Covered:

* Section A: Market Condition
* Market Overview
* Market Trends, 2008-2010
* Market Share by Product Segment of Surveyed Companies
* Distribution Structure
* New Product Development Trends
* Technology Character in DNA Diagnostic Product Development
* Future of Market
* Issues and Strategy for the DNA-Based Diagnostic and Test Business
* Section B: Company Case Studies (15 Companies)
* Section C: Additional Companies in DNA-based Diagnostics, by Market Segment

Companies Mentioned:

* Abbott Molecular Diagnostics
* Becton Dickinson (BD) Diagnostics
* BioMérieux USA/BioTheranostics
* Celera Corp.
* Decode Genetics
* Qiagen North America/Digene
* Genomic Health
* Gen-Probe
* Interleukin Genetics

For more information visit
http://www.researchandmarkets.com/research/8325d9/us_dnabased_diagn

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009